Innovation protecting tomorrow

Partner with us, license a technology, or innovate locally here in New Mexico.

Request for Information: Advanced Tissue-engineered Human Ectypal Networks Analyzer (ATHENA)

Commercialization Opportunity

LANS is opening this Request for Information to gauge interest in engaging as an industry partnerwith LANS for collaboration in advancing a next-gen in vitro platform for lead compound and toxicity screening.

Submit your response by email to athena@lanl.gov by 11:59 PM MST on Friday, May 27, 2016.

Background and Technology Description

Over the past 3+ years, Los Alamos scientists have developed a milli-scale surrogate human organ bioreactor, coupled with highly sensitive analytical technologies. Dubbed the Advanced Tissue-engineered Human Ectypal Networks Analyzer (ATHENA), the platform is a human organ construct developed for screening of lead compounds, testing of medical countermeasures, and toxicity testing.

Learn more »


Request for Information: Advance a Ligand and Homogenous Catalyst Platform

Commercialization Opportunity

LANS is opening this Request for Information to gauge interest in engaging as an industry partnerwith LANS for collaboration in advancing a Laboratory-developed ligand and catalyst platform.

Submit your response by email to catalysis@lanl.gov by 11:59 PM MST on Friday, April 29, 2016.

Background and Technology Description

Los Alamos scientists have prepared new ligands from inexpensive starting materials, and new metal complexes with these ligands, investigating their activity and selectivity towards the hydrogenation of carbonyl containing compounds (e.g. simple and functionalized ketones, esters). Several structurally unprecedented catalysts have been synthesized, and the hydrogenation of esters and ketones has been demonstrated with high activities and selectivities.

Learn more »


Request for Proposals: Platform for Pre-Symptomatic Detection of Citrus Disease 

Commercialization Opportunity

LANS is currently seeking an industry partner(s) to assist with the commercial deployment of the detection platform described below. Submit your Commercialization Proposal to lanldx@lanl.gov before 11:59 PM MST on Thursday, April 28, 2016.

Background and Technology Description

The citrus industry is under a serious threat from Huanglongbing (HLB), which has been by far the most devastating disease of citrus. HLB is a vector-borne disease. Candidatus Liberibacter is the HLB causative agent and is transmitted by Asian Citrus Psyllid (ACP). There is no naturally occurring HLB-resistant citrus cultivar nor is there any cure.

Los Alamos is designing an in-house droplet digital polymer chain reaction (ddPCR) platform to enable rapid, high throughput and cost-effective detection of HLB pre-symptomatic biomarkers.

LANS is seeking partners for the commercialization of this technology to achieve its widespread use. Commercialization will potentially entail further validation of the biomarkers identified from the greenhouse data using field samples, and design of a next-generation ddPCR by improving multiplexing and throughput, to yield a ddPCR platform for detection.

Learn more »

Technology Opportunities

Periodically the Laboratory notifies the public of technologies and capabilities that may be of interest.  These technologies may extend from recent inventions, technology opportunity or capabilities that may have utility outside the Laboratory.  If you are interested in any of the following LANS capabilities, please contact the Business Development Team.

Visit Blogger Join Us on Facebook Follow Us on Twitter See our Flickr Photos Watch Our YouTube Videos Find Us on LinkedIn Find Us on iTunesFind Us on GooglePlay